New combo therapy aims to shrink stomach tumors
NCT ID NCT07356466
First seen Jan 24, 2026 · Last updated May 22, 2026 · Updated 19 times
Summary
This study tests whether adding pucotenlimab and lenvatinib to standard chemotherapy (SOX) helps shrink tumors more than chemotherapy alone in people with advanced HER2-negative stomach or gastroesophageal junction cancer. About 100 adults aged 18-75 who have not had prior treatment for advanced disease will participate. The main goal is to see how many patients have their tumors shrink significantly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC (STOMACH) CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Fujian Medical University Union Hospital
Fuzhou, Fujian, 350001, China
Conditions
Explore the condition pages connected to this study.